Are polivy's side effects typical or rare?

Polivy (polatuzumab‑vedotin) is an antibody‑drug conjugate that’s used mainly for relapsed or refractory diffuse large B‑cell lymphoma (DLBCL). Like any therapy, it has a range of side‑effects, and they fall into two broad categories: common (typical) and less common (rare).

| Side‑effect category | Typical (common) | Incidence (≈) | Rare (less common) | Incidence (≈) |
|---------------------------|----------------------|-------------------|------------------------|-------------------|
| Hematologic | Neutropenia, anemia, thrombocytopenia | 40‑70 % (neutropenia is the most frequent) | Febrile neutropenia, severe cytopenias | <10 % |
| Gastro‑intestinal | Nausea, vomiting, diarrhea, constipation | 30‑50 % | Severe GI toxicity (e.g., ileus) | <5 % |
| Neurologic | Peripheral sensory neuropathy (tingling, numbness) | 25‑40 % | Severe neuropathy requiring dose reduction or discontinuation | <5 % |
| Infusion‑related | Fever, chills, rash, hypotension during infusion | 15‑25 % | Severe anaphylaxis, severe hypotension | <1 % |
| Dermatologic | Dry skin, rash, pruritus | 10‑20 % | Severe skin reactions (e.g., Stevens–Johnson syndrome) | <1 % |
| Pulmonary | Dyspnea, cough | 5‑10 % | Pulmonary embolism, interstitial lung disease | <1 % |

What does “typical” mean?

- Common side‑effects are those you’ll see in a substantial fraction of patients (often >10 %). They’re usually manageable with dose adjustments, supportive care (e.g., anti‑emetics, growth factors for neutropenia), or treatment interruption.
- Rare side‑effects are much less frequent (often <1 % of patients). They tend to be more serious and may require hospitalization or permanent discontinuation of Polivy.

How to handle side‑effects

1. Early reporting – If you notice any symptom (fever, new rash, tingling), let your oncology team know right away.
2. Pre‑medication – Antihistamines, steroids, and anti‑emetics are often given before the infusion to reduce infusion reactions.
3. Monitoring – Regular CBCs, metabolic panels, and neuropathy assessments help catch problems before they become severe.
4. Dose modifications – Your oncologist may delay, reduce, or pause dosing if side‑effects become problematic.
5. Supportive measures – Growth factor support (e.g., G‑CSF) for neutropenia, vitamin‑B12 and folate for neuropathy, and hydration for GI symptoms.

Bottom line

Most patients on Polivy experience at least one of the typical side‑effects such as neutropenia, nausea, or neuropathy. Rare but potentially serious events—like severe anaphylaxis, life‑threatening infections, or profound neuropathy—do occur, but they’re much less common. The key is vigilant monitoring and open communication with your oncology team so that side‑effects can be addressed promptly and effectively.